explore -WSS

explore

author：explore 2025-09-30 19:27:04 - browse：1154

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Presidential fundraising highlights so far: Trump brings in more than DeSantis

WSS

Micronoma's microbiome cancer diagnostic approach under fire

Biden’s NIH nominee is languishing in Congress

White House announces new plan to address the growing threat of xylazine in overdose crisis

Biden’s NIH nominee is languishing in Congress

The aspartame in Diet Coke probably isn’t giving you cancer

Dozens of beaches across Northeast closed for swimming due to high levels of bacteria in water

hotspot

explore

focus

Bright Health sells Medicare Advantage business to Molina

Mega Millions pot grows to $1.25 billion after no winner

Hepatitis C has a cure — but many Americans still lack access to it

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

Jerome Adams on the need for new antivirals for Covid

Teachers share how revamped forgiveness program helped with their student loans

As demand for Covid shots wanes, Moderna seeks its next success

Biden targets hefty hospital 'facility fees' that often surprise patients

Wildfire smoke exposes gaps in outdoor worker protections

Biden’s NIH nominee is languishing in Congress

focus

Biden’s NIH nominee is languishing in Congress

US sending controversial cluster munitions to Ukraine until other ammo is ready: Kirby

What the airline industry can learn from medicine

The U.S. needs a new definition of substance use “recovery”

EQRx, failed developer of low

Teachers share how revamped forgiveness program helped with their student loans

Wikipedia

leisure time

hotspot

knowledge